History
Explore our Journey of Excellence in Pharmaceutical Manufacturing.
Tianming Pharmaceuticals: to be a global pharmaceutical leader driven by innovation
Tianming Pharmaceuticals is a high-tech enterprise focusing on the research and development, production and sales of new drugs. Our company owns three major production bases as well as two major R&D centers. In addition, the company has established sales subsidiaries in India and Bangladesh, and has established extensive business contacts with partners in many countries around the world.
In the field of R&D, Tianming Pharmaceuticals has a R&D team of more than 100 professional talents, dedicated to the research and development of antibiotics and diabetes drugs, and its R&D level is in a leading position in China. Our company has unique technical advantages in the production process of pharmaceutical raw materials and intermediates, and has passed the ISO9001 international quality system certification, ensuring high standards and continuous innovation of product quality.
Our Development History
Our Culture
Corporate Vision
To develop innovative medicines and realize the dream of health
Corporate Mission
To contribute to the healthy life of human society while pursuing the material and spiritual happiness of all employees
Corporate Values
Honesty and Trustworthiness, Unity and Mutual Assistance, Pragmatism and Responsibility, Innovation and Progress
What's News
Latest News at Tianming
ICH Q11 Starting Material Selection: A Practical Guide for Pharmaceutical Intermediate Buyers
Learn how ICH Q11 starting material rules affect pharmaceutical intermediate sourcing—supplier boundaries, COA red flags, and a practical buyer’s checklist.
Polymorphism in Pharmaceutical Intermediates: Why Solid Form Control Matters
This guide explains what polymorphism means for intermediate buyers, how ICH Q6A Decision Tree #4 governs solid form control, which COA red flags signal polymorph gaps, and three questions every buyer should ask their supplier before committing to a purchase.
Elemental Impurities (ICH Q3D) in Pharmaceutical Intermediates: A Buyer’s Guide
This guide explains the four element classes, the 30% control threshold that determines whether routine testing is required, the difference between ICP-MS and ICP-OES analytical methods, and five red flags on supplier COAs that signal inadequate elemental impurity control.